December 6, 2016December 6, 2016

Positive Trial Results of Pulmaquin Reported for Non-CF Bronchiectasis Patients with Chronic Lung Infections

Bronchiectasis, News

Aradigm reported positive results from the ORBIT-3 (NCT01515007 ) and ORBIT-4 (NCT02104245) Phase 3 clinical trials assessing Pulmaquin for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE) in patients with chronic lung infection by Pseudomonas aeruginosa bacteria. The pivotal clinical trials ... Read more

June 4, 2014November 6, 2015

Aradigm Receives $5 Million for the First Patient to Test Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Bronchiectasis, News

Aradigm Corporation has received a $5 million milestone payment from Grifols S.A. for dosing of the first patient in a phase III study of the ORBIT-3 (once-daily respiratory bronchiectasis inhalation ... Read more